Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma

NCT03046953

Last updated date
Study Location
University College London Hospital
London, , , United Kingdom
Contact
0121 414 7673

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

0121 414 7673

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
16 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female patients aged ≥ 16 years

- Life expectancy > 12 weeks

- ECOG performance status ≤ 2

- Relapsed or refractory* peripheral T-cell lymphoma including the following histologies: peripheral T-cell lymphoma not otherwise specified (PTCL NOS) , angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), enteropathy associated T-cell lymphoma (EATL), extranodal NK/T- cell lymphoma (ENKL), transformed mycosis fungoides (LCT MF), hepatosplenic T-cell lymphoma (HSTCL) * For all relapsed patients, relapse must be confirmed by tissue biopsy (or bone marrow trephine if no other tissue available). For refractory patients, a biopsy must have been obtained within the last 3 months

- Failed at least 1 prior therapy (but no upper limit of prior regimens)

- Adequate haematological function defined by at registration:

- absolute neutrophil count (ANC) ≥ 1.0 × 109/L, (unsupported)

- platelet count ≥ 75 × 109/L, (unsupported)

- haemoglobin ≥ 9 g/dL (may have been transfused)

- Adequate hepatic function defined by:

- total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range

- AST or ALT levels ≤ 2.5 × ULN for all patients or AST and ALT levels ≤ 5 x ULN (for subjects with documented metastatic disease to the liver)

- Adequate renal function defined by an estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method)

- CT measurable disease with at least 1 lesion having short axis > 1.5cm or splenomegaly > 14cm in cranio-caudal length attributable to relapsed/non responding lymphoma

- Negative serum pregnancy test at screening for women of childbearing potential.

- Highly effective contraception for both male and female patients if the risk of conception exists. (Note: women of childbearing potential and men able to father a child must agree to use 2 highly effective contraception, defined as methods with a failure rate of less than 1 % per year. Highly effective contraception is required from consent, throughout and for at least 60 days after avelumab treatment.

- Ability to give informed consent

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Patients are not eligible for the trial if they fulfill any of the following exclusion
criteria:


- All patients with active CNS involvement of lymphoma


- Prior organ transplantation, including allogeneic stem cell transplantation


- Significant acute or chronic infections including, among others:


- Known history of testing positive test for human immunodeficiency virus (HIV) or
known acquired immunodeficiency syndrome (AIDS),


- Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening
(positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test
positive)


- Current use of immunosuppressive medication, EXCEPT for the following:


- intranasal, inhaled, topical steroids, or local steroid injection (e.g.,
intra-articular injection); Systemic corticosteroids at a maximum dose of ≤ 1
mg/kg of prednisone or equivalent during screening (to be stopped by day 1 of
trial treatment); Steroids as premedication for hypersensitivity reactions (e.g.,
CT scan premedication).


- Active autoimmune disease that might deteriorat e when receiving an immunostimulatory
agent. Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid
disease not requiring immunosuppressive treatment are eligible


- Known prior severe hypersensitivity to investigational product or any component in its
formulations, including known severe hypersensitivity reactions to monoclonal
antibodies (NCI CTCAE v4.03 Grade ≥ 3)


- Persisting toxicity related to prior therapy of Grade >1 NCI-CTCAE v 4.03; however,
alopecia and sensory neuropathy Grade ≤ 2 or other Grade ≤ 2 not constituting a safety
risk based on investigator's judgment are acceptable are acceptable


- Pregnancy or lactation


- Known alcohol or drug abuse


- Clinically significant (i.e., active) cardiovascular disease: cerebral vascular
accident/stroke (< 6 months prior to registration), myocardial infarction (< 6 months
prior to registration), unstable angina, congestive heart failure (≥ New York Heart
Association Classification Class II), or serious cardiac arrhythmia requiring
medication.


- Other severe acute or chronic medical conditions including colitis, inflammatory bowel
disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent
(within the past year) or active suicidal ideation or behaviour; or laboratory
abnormalities that may increase the risk associated with study participation or study
treatment administration or may interfere with the interpretation of study results
and, in the judgment of the investigator, would make the patient inappropriate for
entry into this study


- Vaccination within 4 weeks of the first dose of avelumab and while on trial is
prohibited except for administration of inactivated vaccines


- Active infection requiring systemic therapy


- Major surgery within 4 weeks of trial entry


- Patients and partners of childbearing potential not willing to use two methods of
effective contraception during and for 60 days after therapy

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

T-Cell Lymphoma Relapsed, T-Cell Lymphoma RefractoryAvelumab in Relapsed and Refractory Peripheral T-cell Lymphoma
NCT03046953
  1. London,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma
Official Title  ICMJE A Phase 2a Trial of Avelumab, an Anti-PDL1 Antibody, in Relapsed and Refractory Peripheral T-cell Lymphoma
Brief Summary The AVAIL-T trial is a trial to find out how effective avelumab is at treating patients with primary T-cell lymphoma that is refratory to or has relapsed following initial treatment.
Detailed Description

The AVAIL-T trial is designed to find out how effective avelumab is at treating patients with primary T-cell lymphoma that is refratory to or has relapsed following initial treatment. Up to 36 people will be taking part in the AVAIL-T trial at hospitals across the United Kingdom. All patients on the trial will be recruited over 2 years and recieve up to 8 cycles of avelumab treatment. Avelumab is an anti-PD-L1 antibody that will be given as an infusion once every 2 weeks in cycles lasting 28 days. The trial will be looking at the response to aveulumab, by mesuring the change in the tumour size using CT scans, and seeing how long that response is maintained. The trial will also look at toxicity, overall survival, and progression free survival.

In addition we will analyse blood samples and samples of the cancer to understand better how the cancer behaves. This may guide the investigators in developing better treatments in the future.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
Signle Arm trial with basian design
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • T-Cell Lymphoma Relapsed
  • T-Cell Lymphoma Refractory
Intervention  ICMJE Drug: Avelumab
anti-PDL1 antibody
Other Name: MSB0010718C
Study Arms  ICMJE Experimental: Avleumab
Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.
Intervention: Drug: Avelumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 6, 2017)
35
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE August 2021
Estimated Primary Completion Date August 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female patients aged ? 16 years
  • Life expectancy > 12 weeks
  • ECOG performance status ? 2
  • Relapsed or refractory* peripheral T-cell lymphoma including the following histologies: peripheral T-cell lymphoma not otherwise specified (PTCL NOS) , angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), enteropathy associated T-cell lymphoma (EATL), extranodal NK/T- cell lymphoma (ENKL), transformed mycosis fungoides (LCT MF), hepatosplenic T-cell lymphoma (HSTCL) * For all relapsed patients, relapse must be confirmed by tissue biopsy (or bone marrow trephine if no other tissue available). For refractory patients, a biopsy must have been obtained within the last 3 months
  • Failed at least 1 prior therapy (but no upper limit of prior regimens)
  • Adequate haematological function defined by at registration:

    • absolute neutrophil count (ANC) ? 1.0 × 109/L, (unsupported)
    • platelet count ? 75 × 109/L, (unsupported)
    • haemoglobin ? 9 g/dL (may have been transfused)
  • Adequate hepatic function defined by:

    • total bilirubin level ? 1.5 × the upper limit of normal (ULN) range
    • AST or ALT levels ? 2.5 × ULN for all patients or AST and ALT levels ? 5 x ULN (for subjects with documented metastatic disease to the liver)
  • Adequate renal function defined by an estimated creatinine clearance ? 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method)
  • CT measurable disease with at least 1 lesion having short axis > 1.5cm or splenomegaly > 14cm in cranio-caudal length attributable to relapsed/non responding lymphoma
  • Negative serum pregnancy test at screening for women of childbearing potential.
  • Highly effective contraception for both male and female patients if the risk of conception exists. (Note: women of childbearing potential and men able to father a child must agree to use 2 highly effective contraception, defined as methods with a failure rate of less than 1 % per year. Highly effective contraception is required from consent, throughout and for at least 60 days after avelumab treatment.
  • Ability to give informed consent

Exclusion Criteria:

Patients are not eligible for the trial if they fulfill any of the following exclusion criteria:

  • All patients with active CNS involvement of lymphoma
  • Prior organ transplantation, including allogeneic stem cell transplantation
  • Significant acute or chronic infections including, among others:

    • Known history of testing positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS),
    • Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive)
  • Current use of immunosuppressive medication, EXCEPT for the following:

    • intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); Systemic corticosteroids at a maximum dose of ? 1 mg/kg of prednisone or equivalent during screening (to be stopped by day 1 of trial treatment); Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
  • Active autoimmune disease that might deteriorat e when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
  • Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade ? 3)
  • Persisting toxicity related to prior therapy of Grade >1 NCI-CTCAE v 4.03; however, alopecia and sensory neuropathy Grade ? 2 or other Grade ? 2 not constituting a safety risk based on investigator's judgment are acceptable are acceptable
  • Pregnancy or lactation
  • Known alcohol or drug abuse
  • Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to registration), myocardial infarction (< 6 months prior to registration), unstable angina, congestive heart failure (? New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
  • Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behaviour; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
  • Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
  • Active infection requiring systemic therapy
  • Major surgery within 4 weeks of trial entry
  • Patients and partners of childbearing potential not willing to use two methods of effective contraception during and for 60 days after therapy
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 16 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Eszter R Nagy, MSc0121 414 7673[email protected]
Contact: Sonia Fox01214149273[email protected]
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03046953
Other Study ID Numbers  ICMJE RG_16-123
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Responsible Party University of Birmingham
Study Sponsor  ICMJE University of Birmingham
Collaborators  ICMJE
  • Bloodwise
  • Pfizer
Investigators  ICMJE
Principal Investigator:Simon Wagner, MDUniveristy of Leicester
PRS Account University of Birmingham
Verification Date November 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP